Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

References

• Rozovski U, Benjamini O, Jain P, et al. Outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation after transplantation failure. J Clin Oncol. 2015;33:1557–1563.
   PubMed Web of Science ®Google Scholar
• Thompson PA, O’Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–3621.
   PubMed Web of Science ®Google Scholar
• Yang Q, Modi P, Newcomb T, et al. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21:1537–1542.
   PubMed Web of Science ®Google Scholar
• Zent CS, Wang XV, Ketterling RP, et al. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progress chronic lymphocytic leukemia in older patients: a trial of the ECOG-Acrin Cancer Research Group (E1908). Am J Hematol. 2016;91:308–312.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Flynn J, Kipps TJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127:79–86.
   PubMed Web of Science ®Google Scholar
• Grosicki S. Ofatumumab for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2015;8:265–272.
   PubMed Web of Science ®Google Scholar
• Lucas DM, Ruppert AS, Lozanski G, et al. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US Intergroup phase III trial E2997. Leuk Lymphoma. 2015;56:3031–3037.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel-an update. Leuk Lymphoma. 2015;23:1–17.
   Google Scholar
• Lepretre S, Dartigeas C, Feugier P, et al. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leuk Lymphoma. 2015;8:1–14.
   Google Scholar
• Maffei R, Colaci E, Fiorcari S, et al. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2016;97:291–302.
   PubMed Web of Science ®Google Scholar
• Shvidel L, Berrebi A. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare? Expert Rev Hematol. 2015;23:1–10.
   Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39:1312–1318.
   PubMed Web of Science ®Google Scholar
• Kwak MS, Yu SJ, Yoon JH, et al. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. J Cancer Res Clin Oncol. 2015;141:2037–2045.
   PubMed Web of Science ®Google Scholar
• Song Y, Xin X, Zhai X, et al. Sequential combination of flavopiridol with taxol synergistically suppresses human ovarian carcinoma growth. Arch Gyenocol Obstet. 2015;291:143–150.
   PubMed Web of Science ®Google Scholar
• Brenner S, Riha J, Giessrigl B, et al. The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. Int J Oncol. 2015;46:324–332.
   PubMed Web of Science ®Google Scholar
• Soner BC, Aktug H, Adikgoz E, et al. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol. In J Mol Med. 2014;34:1249–1256.
   Web of Science ®Google Scholar
• Lee HG, Baek JW, Shin SJ, et al. Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model. Reprod Sci. 2014;21:1153–1160.
   PubMed Web of Science ®Google Scholar
• Jain SK, Bharate SB, Vishwakarma RA. Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev Med Chem. 2012;12:632–649.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986–2999.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804–3816.
   PubMed Web of Science ®Google Scholar
• Blachly JS, Byrd JC. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma. 2013;54:2133–2143.
   PubMed Web of Science ®Google Scholar
• Pepper C, Thomas A, Hoy T, et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2001;114:70–77.
   PubMed Web of Science ®Google Scholar
• Hussain SR, Lucas DM, Johnson AJ, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood. 2008;111:3190–3199.
   PubMed Web of Science ®Google Scholar
• Mahoney E, Byrd JC, Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013;9:434–435.
   PubMed Web of Science ®Google Scholar
• Mahoney E, Lucas DM, Gupta SV, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012;120:1262–1273.
   PubMed Web of Science ®Google Scholar
• Ray B, Agarwal S, Lohani N, et al. Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA. J Biomol Struct Dyn. 2016;17:1–18.
   Google Scholar
• Myatt D, Johnson L, Baumli S, et al. The binding of flavopiridol to blood serum albumin. Chirality. 2010;22(Suppl 1E):E40–43.
   Google Scholar
• Ni W, Ji J, Dai Z, et al. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One. 2010;5:e13792.
   PubMed Web of Science ®Google Scholar
• Cihalova D, Staud F, Ceckova M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother Pharmacol. 2015;76:105–116.
   PubMed Web of Science ®Google Scholar
• Kodaira H, Kusuhara H, Ushiki J, et al. Kinetic analysis of the cooperation of p-glycoprotein (P- gp/Abeb1) and breast cancer resistance protein (Berp/Abeg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol and Exptl Therapeutics. 2010;333:788–796.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al. Flaavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113:2637–2645.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Ruppert AS, Maddocks K, et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res. 2013;37:1195–1199.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Wei L, Rozewski D, et al. Reduced occurrence of tumor flare with flavopiridol followed by combine flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol. 2015;90:327–333.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176–4181.
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27:6012–6018.
   PubMed Web of Science ®Google Scholar
• Messmann RA, Ulmann CD, Lahusen T, et al. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res. 2003;9:562–570.
   PubMed Web of Science ®Google Scholar
• Lanasa MC, Andritsos L, Brown JR, et al. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015;39:495–500.
   PubMed Web of Science ®Google Scholar
• Zeidner JF, Foster MC, Blackford AL, et al. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015;100:1172–1179.
   PubMed Web of Science ®Google Scholar
• Blum KA, Ruppert AS, Woyach JA, et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia. 2011;25:1444–1451.
   PubMed Web of Science ®Google Scholar
• Ji J, Mould DR, Blum KA, et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res. 2013;19:1269–1280.
   PubMed Web of Science ®Google Scholar
• Ali R, Ozkalemkaş F, Ozkocaman V, et al. Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukaphersis. Ann Hematol. 2004;83:61–63.
   PubMed Web of Science ®Google Scholar
• Howard SC, Trifilio S, Gregory TK, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95:563–573.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Dutcher JP, Leaf AN, et al. Objective response of multiple myeloma to cyclosporine A. Leuk Lymphoma. 1994;16:167–170.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15:1451–1459.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao X, Phelps MA, et al. A novel liposomal formulation of flavopiridol. Int J Pharm. 2009;365:170–174.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Lozanski G, Ruppert AS, et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012;26:1442–1444.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Ruppert AS, Blum K, et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica. 2012;97:423–427.
   PubMed Web of Science ®Google Scholar